Clinical footprint PlasmaJet has treated over 45,000 patients across more than 20 countries, indicating a broad clinical adoption and a proven track record that can reassure prospective buyers and drive international expansion conversations.

Product leadership As the first true plasma surgery system with a robust patent portfolio and a focus on plasma energy for dissection, cutting, coagulation, and vaporization, there are clear talking points for differentiating against traditional devices and competing technologies.

Financial scale Revenue is in the range of 50 to 100 million, suggesting a mid-market company with growth potential and a compelling case for expedited procurement discussions, financing options, or volume-based pricing for hospital systems.

Global access Operations in multiple countries combined with a scalable tech stack and digital presence indicate opportunities for channel partnerships, distributor networks, and international service agreements to accelerate sales cycles.

Clinical value The device enables precise plasma energy for dissection, cutting, coagulation, and tissue removal, providing a strong value proposition for surgeons focused on improved clinical outcomes and faster patient recovery, which can be leveraged in ROI and case-study-driven sales plays.